Results 21 to 30 of about 27,503 (257)

Effects of Combination Treatment With Dipeptidyl Peptidase IV Inhibitor and Sulfonylurea on Glucose Levels in Rats

Journal of Pharmacological Sciences, 2004
The effects of orally administered dipeptidyl peptidase IV (DPP-IV) inhibitor on the glucose-lowering effect of glibenclamide are still unknown. We evaluated the effects of combination treatment with a long-lasting DPP-IV inhibitor, K579 ((S)-1-[4-methyl-
Kotaro Takasaki, Takao Nakajima, Kimihisa Ueno, Yuji Nomoto, Katsuya Higo   +4 more
doaj   +1 more source

The pleiotropic cardiovascular effects of dipeptidyl peptidase‐4 inhibitors [PDF]

British Journal of Clinical Pharmacology, 2018
Patients with Type 2 diabetes have an excess risk for cardiovascular disease. One of the several approaches, included in the guidelines for the management of Type 2 diabetes, is based on dipeptidyl peptidase 4 (DPP‐4; also termed CD26) inhibitors, also called gliptins.
Avogaro, Angelo, Fadini, Gian Paolo
openaire   +3 more sources

Effects of dipeptidyl peptidase‐4 inhibition in vivo: Dipeptidyl peptidase‐4 inhibitor/gut microbiome crosstalk suggests novel therapeutic options for diabetes management [PDF]

Journal of Diabetes Investigation
Takuma Yasuda, Norio Harada, Nobuya Inagaki   +2 more
doaj   +2 more sources

An open-label pilot study on preventing glucocorticoid-induced diabetes mellitus with linagliptin

Journal of Medical Case Reports, 2018
Background Numerous patients develop diabetes in response to glucocorticoid therapy. This study explored the efficacy, safety, and preventive potential of the dipeptidyl peptidase-4 inhibitor, linagliptin (TRADJENTA®), in the development of ...
Yoshia Miyawaki, Ken-Ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Yoshinori Matsumoto, Katsue Sunahori-Watanabe, Tomoko Kawabata, Jun Wada   +12 more
doaj   +1 more source

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

Journal of Pharmacological Sciences, 2017
Saxagliptin, a potent and selective DPP-4 inhibitor, exhibits a slow dissociation from DPP-4. We investigated the sustained effects of saxagliptin on renal DPP-4 activity in a washout study using renal tubular (HK-2) cells, and in a pharmacodynamic study
Masako Uchii, Mariko Sakai, Yuhei Hotta, Satoshi Saeki, Naoya Kimoto, Akinori Hamaguchi, Tetsuya Kitayama, Shunji Kunori   +7 more
doaj   +1 more source

Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin

Journal of Diabetes Investigation, 2021
Aims/Introduction To identify the effect of combination therapy with a dipeptidyl peptidase‐4 inhibitor and a sodium–glucose cotransporter 2 inhibitor compared with switching from a dipeptidyl peptidase‐4 inhibitor to a sodium–glucose cotransporter 2 ...
Aika Miya, Akinobu Nakamura, Kyu Yong Cho, Shinichiro Kawata, Hiroshi Nomoto, So Nagai, Hajime Sugawara, Shinji Taneda, Kazuhisa Tsuchida, Kazuno Omori, Hiroki Yokoyama, Jun Takeuchi, Shin Aoki, Yoshio Kurihara, Tatsuya Atsumi, Hideaki Miyoshi   +15 more
doaj   +1 more source

Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats

Journal of Pharmacological Sciences, 2016
Saxagliptin, a potent and selective DPP-4 inhibitor, is characterized by its slow dissociation from DPP-4 and its long half-life and is expected to have a potent tissue membrane-bound DPP-4-inhibitory effect in various tissues.
Junichi Ikeda, Naoya Kimoto, Tetsuya Kitayama, Shunji Kunori   +3 more
doaj   +1 more source

Vildagliptin: the first innovative DDP-4 inhibitor

Сахарный диабет, 2010
A review of the main stages of investigation undertaken by Novartis Pharmaceuticals in search of a new molecule for the treatment of type 2 diabetesmellitus, dipeptidyl peptidase-4 (DPP-4) inhibitor (Vildaglyptin). The data on specificity and selectivity
Edvin Villkhauer
doaj   +1 more source

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors

Journal of Clinical Medicine, 2022
Dipeptidyl peptidase 4 (DPP-4) is a novel adipokine and may be involved in the association between adipose tissue and metabolic syndrome. We investigated DPP-4 and adiponectin levels in the serum, subcutaneous adipose tissue (SAT), and epicardial adipose tissue (EAT), and their relationship with preoperative factors, as well as comparing the DPP-4 ...
Ikuko Shibasaki, Toshiaki Nakajima, Taira Fukuda, Takaaki Hasegawa, Hironaga Ogawa, Go Tsuchiya, Yusuke Takei, Masahiro Tezuka, Takashi Kato, Yuta Kanazawa, Yasuyuki Kano, Toshiyuki Kuwata, Motoshi Ouchi, Shigeru Toyoda, Yoshimasa Aso, Hirotsugu Fukuda   +15 more
openaire   +2 more sources

Dipeptidyl Peptidase-4 Inhibitor

Korean Journal of Medicine, 2014
Recent advances in incretin biology have led to the development of a new class of oral anti-diabetic drugs. To date, there are two known incretin hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), of which the former is a more important therapeutic target for type 2 diabetes.
openaire   +1 more source